Aiming to discover new disease modifying treatments and working towards a cure for Parkinson's disease.

The Company’s primary objective is the discovery of drugs that can prevent or inhibit the progression of Parkinson’s disease. The Company’s primary goal is to discover and co-develop drugs that stop the disease progression and the Company also aims to exploit any new drugs that lead to the improvement of symptoms.   The Company uses an in-vivo (i.e. in living tissue rather than test tubes) drug discovery platform.

  • Product

    Life Sciences SEIS
  • Sector

    Drug discovery
  • Status

    Closed
  • HMRC

    Advanced Assurance